Arcellx

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ).

Why Is Arcellx (ACLX) Stock Up 25% Today?

Gilead Sciences

Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company.

Gilead to co-develop Arcellx's multiple myeloma drug

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--( BUSINESS WIRE )--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12 months ago or had their 12-month follow-up visit by November 22, 2022 have reached CR/sCR -- -- No cases of Grade > 3 CRS at RP2D and no delayed neurotoxicity or parkinsonian-like events -- -- First patients dosed in iMMagine-1 Phase 2 clinical trial with pivotal drug product -- -- Initiated the Phase 1 clinical trial of ACLX-002 for the treatment of patients with AML/MDS -- -- Management to host a live webcast event with an expert panel of clinicians to discuss the CART-ddBCMA clinical results on Sunday, December 11, 2022, at 11:00 AM CT -- REDWOOD CITY, Calif. , Dec. 9, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, dosing of first patients in its iMMagine-1 Phase 2 clinical trial with pivotal drug product, and the initiation of the Phase 1 clinical trial of ACLX-002 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif.

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

Amylyx Pharmaceuticals

Belite Bio Inc

CinCor Pharma

Credo Technology Group Holding Ltd

Golden Sun Education Group Ltd

AMTD Digital

Mobileye Global Inc

Nuvectis Pharma

The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.

These Are the 10 Best-Performing IPOs in 2022 Through October

-- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA  -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December -- -- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022, at 11:00 AM CT -- REDWOOD CITY, Calif. , Nov. 14, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the third quarter ended September 30, 2022.

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

-- ASH abstract contains previously presented data from June 2022 -- -- New clinical data from a recent data cut will be presented at ASH -- -- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022, at 11:00 a.m. CT -- REDWOOD CITY, Calif.

Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet

REDWOOD CITY, Calif. , Sept. 7, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 3:30 p.m.

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts.

Arcellx: Promising Up And Coming Player In The CAR-T Space

Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology.

Arcellx: The Best Is Yet To Come

-- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares -- -- Presented continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial being evaluated in patients with r/r MM at the 2022 ASCO Annual Meeting -- -- Preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics  -- REDWOOD CITY, Calif. , Aug. 15, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2022.

Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results

REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D.

Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share.

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

-- Public Offering of 7,000,000 Shares of Common Stock for Gross Proceeds of $112 Million -- REDWOOD City, Calif. , June 15, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of an upsized underwritten follow-on offering of 7,000,000 shares of common stock at a price to the public of $16.00 per share.

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering

-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached CR/sCR -- -- 13 of 16 patients (81%) dosed more than 12 months ago reached CR/sCR; 8 (50%) with EMD; 9 (56%) remain in ongoing response with a median follow up of 17.7 months -- -- No cases of Grade ≥3 CRS and no delayed neurotoxicity or parkinsonian-like events observed at RP2D (n=25) -- -- Phase 2 pivotal study on track to initiate by YE 2022 -- -- Management to host live webcast event on Sunday, June 5, 2022, at 7:00 p.m. CDT to discuss new positive CART-ddBCMA data with a panel of clinician experts -- FOSTER CITY, Calif.

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

Iovance Biotherapeutics

Mirati Therapeutics

SpringWorks Therapeutics Inc

Zymeworks Inc

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Clinical Oncology annual meeting.

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

FOSTER CITY, Calif. , May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer.

Arcellx Appoints Michelle Gilson as Chief Financial Officer

-- Replaces Lewis T. "Rusty" Williams, M.D.

Arcellx Appoints Olivia Ware to Board of Directors

-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) --  -- Management to host live webcast event during the 2022 ASCO Annual Meeting on Sunday, June 5, 2022, at 7:00 p.m. CDT to discuss new CART-ddBCMA data with a panel of clinician experts -- FOSTER CITY, Calif.

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

-- ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and overcome tumor heterogeneity -- -- Initial data anticipated in 2023 -- FOSTER CITY, Calif. , May 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the first patient has been dosed in its open-label, multicenter ACLX-001 Phase 1 clinical trial (NCT04155749) to evaluate the company's novel ARC-SparX program in patients with relapsed or refractory multiple myeloma (r/r MM).

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

100% ORR; 75% CR/sCR; and evidence of durable clinical benefit in a population with poor prognostic features observed in the dose escalation cohorts with CART-ddBCMA FOSTER CITY, Calif. , May 9, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the publication of clinical data from its dose escalation cohorts in its ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM).

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:00 p.m.

Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference

-- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, June 5, 2022, at 7:00 PM CDT -- FOSTER CITY, Calif., April 27, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that new clinical data from its Phase 1 Study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented in an oral abstract session at the 2022 ASCO Annual Meeting taking place June 3-7, 2022, in Chicago, Illinois.

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

News for Arcellx Stock (ACLX)